SLDB
Solid Biosciences Inc. (SLDB) Economic Moat Analysis (2026)
Overall Score
Profitability Returns
TTM margins remain at 0% across gross, operating, EBITDA, pretax, and net profit, indicating no current earnings power.
Returns are deeply negative, with ROA at -49.2%, ROE at -72.3%, and ROIC at -53.8%, showing no evidence of a durable economic moat from profitability.
Balance Sheet Strength
Liquidity is very strong with a current ratio of 13.8x and cash ratio of 5.6x, giving the company substantial near-term flexibility.
Leverage remains low, with debt-to-equity at 0.05x and debt-to-assets at 0.05x, though the solvency ratio is negative and the business is still loss-making.
Cash Flow Quality
Operating cash flow and free cash flow are both negative, with FCF yield at -19.6% and FCF to firm at -187.8M, indicating weak cash generation.
Cash conversion remains poor despite a high income quality ratio of 0.90, because the underlying business is still consuming cash rather than producing it.
Competitive Positioning
There is no clear evidence of pricing power or scale advantages in the current metrics, as revenue, margins, and returns remain absent or negative.
The balance sheet provides survival capacity, but the operating profile does not yet support a durable moat or strong competitive differentiation.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Solid Biosciences Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

